



GB04/3423



INVESTOR IN PEOPLE

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

REC'D 27 AUG 2004


WIPO PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

Dated 17 August 2004



Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

 Cardiff Road
 Newport
 South Wales
 NP10 8QQ

1. Your reference

P018301GB DAA

06 OCT 2003

2. Patent application number

(The Patent Office will fill this part in)

0323335.0

070CT03 E842437-1 D02246
P01/7700 0.00-0323335.0

3. Full name, address and postcode of the or of each applicant (underline all surnames)

 Danisco A/S
 Langebrogade 1
 PO Box 17
 DK-Copenhagen K
 Denmark

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its incorporation

Denmark

J66873 002

4. Title of the invention

COMPOSITION

5. Name of your agent (if you have one)

D Young & Co

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

 21 New Fetter Lane
 London
 EC4A 1DA

Patents ADP number (if you know it)

59006

6. Priority: Complete this section if you are declaring priority from one or more earlier patent applications, filed in the last 12 months.

Country

Priority application number

(if you know it)

Date of filing
(day / month / year)

7. Divisionals, etc: Complete this section only if this application is a divisional application or resulted from an entitlement dispute (see note f)

Number of earlier UK application
(day / month / year)

8. Is a Patents Form 7/77 (Statement of inventorship and of right to grant of a patent) Yes required in support of this request?

Answer YES if:

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an applicant, or
- c) any named applicant is a corporate body.

Otherwise answer NO (See note d)

9. Accompanying documents: A patent application must include a description of the invention. Not counting duplicates, please enter the number of pages of each item accompanying this form:

Continuation sheets of this form

Description 43

Claim(s) 7

Abstract 1 *on*

Drawing(s) 5 *+5*

10. If you are also filing any of the following, state how many against each item.

Priority documents 0

Translations of priority documents 0

Statement of inventorship and right 0
to grant of a patent (Patents Form 7/77)

Request for a preliminary examination 1
and search (Patents Form 9/77)


Request for a substantive examination 0
(Patents Form 10/77)

0

Any other documents (please specify)

11. I/We request the grant of a patent on the basis of this application.

Signature(s)



Date 06 October 2003

12. Name, daytime telephone number and e-mail address, if any, of person to contact in the United Kingdom

D Young & Co (Agents for the Applicants)

David Alcock

023 8071 9500

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered YES in part 8, a Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- Part 7 should only be completed when a divisional application is being made under section 15(4), or when an application is being made under section 8(3), 12(6) or 37(4) following an entitlement dispute. By completing part 7 you are requesting that this application takes the same filing date as an earlier UK application. If you want the new application to have the same priority date(s) as the earlier UK application, you should also complete part 6 with the priority details.

COMPOSITION

The present invention relates to a composition that exhibits a microbicidal or microbiostatic action.

5

Background

Bacteriocins are antimicrobial proteins or peptides that can be produced by certain bacteria, which can kill or inhibit the growth of closely related bacteria. The bacteriocins 10 produced by lactic acid bacteria are of particular importance since they have great potential for the preservation of food and for the control of foodborne pathogens. (Wessels et al. 1998.)

15 The most well known bacteriocin is nisin, which is the only bacteriocin currently authorised as a food additive. Nisin is produced by fermentation of the dairy starter culture bacterium *Lactococcus lactis* subsp. *lactis*, and is sold as the commercial extract Nisaplin® Natural Antimicrobial (Danisco). Nisin has an unusually broad antimicrobial spectrum for a bacteriocin, being active against most Gram-positive bacteria (e.g. species of *Bacillus*, *Clostridium*, *Listeria*, lactic acid bacteria). It is not normally effective 20 against Gram-negative bacteria, yeasts or moulds. Nisin is allowed as a food preservative worldwide but its levels of use and approved food applications are strictly regulated, varying from country to country.

25 Other bacteriocins have since been discovered with potential as food preservatives, e.g. pediocin, lacticin, sakacin, lactococcin, enterococin, plantaricin, leucocin. These are also active, although usually with a more narrow spectrum, against Gram-positive bacteria. Their food use is at present restricted to production of the bacteriocin *in situ*, i.e. by growth of the producer organism within the food.

30 Antioxidants are widely used in food products susceptible to oxidative degeneration. An antioxidant is defined by the Food and Drug Administration (21CFR 170.3) as "a substance used to preserve food by retarding deterioration, rancidity, or discoloration due to oxidation". Spices or plant extracts can be used in food as antioxidants and to impart flavour. One advantage of such extracts is that they are perceived as natural 35 ingredients when compared to chemical antioxidants such as butyl hydroxyanisole (BHA)

and butylated hydroxytoluene (BHT). Plants of the family Labiatae contain several well known herbs. Extracts from these plants have been shown to have antioxidant and, in some cases, antimicrobial activity (Nychas & Skandamis, 2003; Smid and Gorris, 1999; Loliger, 1989). Such extracts may be essential oils and oleoresins (extracts with 5 essential oil content used in flavours and fragrances) or "deodorised", extracts that have a high phenolic diterpene content and low level of flavour-inducing compounds.

Essential oils are extracted by simple steam distillation of the plant material. The most effective antioxidant compounds in rosemary and sage are reported to be carnosic acid, 10 carnosol and rosmarinic acid (Cuvelier et al. 1996). Carnosic acid, a phenolic diterpene ($C_{20}H_{28}O_4$), occurs naturally in leaves of plants of the Labiatae family, particularly rosemary and sage, but also thyme and marjoram. Dried leaves of rosemary or sage contain 1.5 – 2.5% carnosic acid and 0.3 – 0.4% carnosol (US6231896). Carnosol is an 15 oxidative artefact of carnosic acid (Wenkert et al. J. Org. Chem 30:2931, 1965). The oxidation takes place in the presence of harvesting in the leaves left to dry in the air and if the leaves are subjected to extraction with solvents. Rosmanol may also be a product of the oxidation of carnosic acid.

Food safety and prevention of food spoilage is an ever present concern worldwide, 20 particularly with the increasing trend for convenience foods such as ready to eat meals, soups, sauces or snacks. Spoilage of food is a major economic problem for the food manufacturer. Food manufacturers need to protect the health and safety of the public by delivering products that are safe to eat. Such food must have a guaranteed shelf life, either at chilled or ambient temperature storage. Consumers prefer good tasting food of 25 high quality - this is difficult to achieve with chemical preservatives, harsh heating regimes and other processing measures. Food safety and protection is best achieved with a multiple preservation system using a combined approach of milder processing and natural preservatives. Foodborne micro-organisms are also less able to adapt and grow in food preserved with different preservative measures.

30 There is much concern about food safety and the growth of food pathogens such as *Listeria monocytogenes*. This particular pathogen can grow at low temperatures, which are often used as an additional preservative measure. Foodborne pathogens can sometimes adapt to different preservatives and storage conditions, thus a combination of 35 preservative measures can be more successful than individual measures.

There is an increasing need to develop economical, natural and effective food preservative systems to meet the public demand for convenient, natural, safe, healthy, good quality food products with guaranteed shelf life. Bacteriocins such as nisin can be 5 used as preservatives in food to help meet this need. Nisin is a proven safe, natural preservative with GRAS status. Other bacteriocins can be used for preservation if produced *in situ*, by growth of the bacteriocin producer organism in the food.

10 In some cases the bacteriocin levels required to ensure preservation or food safety may prove uneconomical, or are below effective levels due to regulatory and legislation constraints. When bacteriocins are produced *in situ*, the resulting bacteriocin levels may not be high enough to achieve the required preservative effect.

15 The present invention alleviates the problems of the prior art.

In one aspect the present invention provides a composition comprising (a) an antimicrobial material; and (b) an extract obtained from or obtainable from a plant of the Labiatae family, wherein (a) and (b) are different; wherein when the antimicrobial material consists of nisin, the composition comprises carvacrol in an amount of less than 20 0.075wt.% based on the composition and carvone in an amount of less than 15wt.% based on the composition:

25 In one aspect the present invention provides a process for preventing and/or inhibiting the growth of, and/or killing a micro-organism in a material, the process comprising the step of contacting the material with (a) an antimicrobial material; and (b) an extract obtained from or obtainable from a plant of the Labiatae family, wherein (a) and (b) are different; wherein when the antimicrobial material consists of nisin, the composition comprises carvacrol in an amount of less than 0.075wt.% based on the composition and carvone in an amount of less than 15wt.% based on the composition.

30 In one aspect the present invention provides use of (a) an antimicrobial material; and b) an extract obtained from or obtainable from a plant of the Labiatae family, for preventing and/or inhibiting the growth of, and/or killing a micro-organism in a material; wherein (a) and (b) are different; and wherein when the antimicrobial material consists of nisin, the 35 composition comprises carvacrol in an amount of less than 0.075wt.% based on the

composition and carvone in an amount of less than 15wt.% based on the composition.

In one aspect the present invention provides kit for preparing a composition as defined herein, the kit comprising (a) an antimicrobial material; and (b) an extract obtained from 5 or obtainable from a plant of the Labiatae family, wherein (a) and (b) are different; wherein when the antimicrobial material consists of nisin, the composition comprises carvacrol in an amount of less than 0.075wt.% based on the composition and carvone in an amount of less than 15wt.% based on the composition, in separate packages or containers; optionally with instructions for admixture and/or contacting and/or use.

10

Aspects of the invention are defined in the appended claims.

Of the Labiatae plant family, rosemary and sage have antioxidant activity in foods that is mainly related to phenolic diterpenes such as carnosic acid and carnosol, as well as 15 other phenolic compounds, including phenolic triterpenes such as betulinic acid, oleanolic acid and ursolic acid; and rosmarinic acid. Antimicrobial activity has been attributed to some of these compounds, all of which can be obtained by selective extraction from the plants. The phenolic diterpenes, phenolic triterpenes and rosmarinic acid are distinct from the essential oils and oleoresins that are often used in flavours and 20 fragrances. The high flavour and odour levels of essential oils is not conducive to their use in food. One skilled in the art would expect a combination of an antimicrobial material and an extract from the Labiatae plant family to provide a simple additive bactericidal or bacteriostatic effect. However, *in vitro* studies described herein have demonstrated synergistic enhancement of bacteriocin activity by a deodorised extract of 25 *Rosmarinus officinalis*. This enhanced activity was also observed in a food model, increasing bacteriocin (for example nisin) kill and growth control of Gram-positive bacteria. Enhanced bacteriocin activity was also observed with rosemary extracts specifically prepared to contain high levels of the phenolic diterpenes carnosol and carnosic acid, indicating these compounds play an important role in the synergy. 30 Enhanced bacteriocin activity was also observed with rosmarinic acid.

The present invention provides a synergistic combination of components for preventing and/or inhibiting the growth of, and/or killing a micro-organism in a material, such as foodstuff. This combination of components allows lower levels of the antimicrobial 35 material to be used to provide effective action and prevent the development of tolerance

to the antimicrobial material. This is particularly important in food applications where reduction of dosage and/or avoidance of development of tolerance is desired for commercial and regulatory reasons.

5 For ease of reference, these and further aspects of the present invention are now discussed under appropriate section headings. However, the teachings under each section are not necessarily limited to each particular section.

PREFERRED ASPECTS

10

ANTIMICROBIAL MATERIAL

In one preferred aspect the antimicrobial material is a bacteriocin.

15 The antimicrobial material, such as a bacteriocin, may typically be selected from materials (bacteriocins) that can be used as preservatives in food

Preferably the antimicrobial material is selected from lanthionine containing bacteriocins, *Lactococcus*-derived bacteriocins, *Streptococcus*-derived bacteriocins, *Pediococcus*-derived bacteriocins, *Lactobacillus*-derived bacteriocins, *Carnobacterium*-derived bacteriocins, *Leuconostoc*-derived bacteriocins, *Enterococcus*-derived bacteriocins and mixtures thereof

25 Preferably the antimicrobial material is at least nisin.

Preferably the antimicrobial material consists of nisin.

30 Nisin is a lanthionine-containing bacteriocin (US 5691301) derived from *Lactococcus lactis* subsp. *lactis* (formerly known as *Streptococcus-lactis*) (US 5573801). In a preferred aspect of the present invention the bacteriocin used in the present invention is at least nisin.

35 As discussed in US 5573801 nisin is a polypeptide bacteriocin produced by the lactic acid bacteria, *Lactococcus lactis* subsp. *lactis* (formerly known as *Streptococcus lactis* Group N).

Nisin is reportedly a collective name representing several closely related substances which have been designated nisin compounds A, B, C, D and E (De Vuyst, L. and Vandamme, E. J. 1994. Nisin, a lantibiotic produced by *Lactococcus lactis* subsp. 5 *lactis*: properties, biosynthesis, fermentation and applications. In: Bacteriocins of lactic acid bacteria. Microbiology, Genetics and Applications. Eds.: De Vuyst and Vandamme. Blackie Academic and Professional, London). The structure and properties of nisin are also discussed in the article by E. Lipinska, entitled "Nisin and Its Applications", The 10 25th Proceedings of the Easter School in Agriculture Science at the University of Nottingham, 1976, pp. 103-130 (1977), which article is hereby incorporated by reference. In 1969 the FAO/WHO Joint Expert Committee on Food Additives set 15 specifications for the purity and identity of nisin (FAO/WHO Joint Expert Committee on Food Additives. 1969. Specifications for identity and purity of some antibiotics. 12th Report. WHO Technical Report Series No. 430). This committee recognised nisin as a safe and legal preservative based on extensive toxicological testing. Nisin has the food 20 additive number E234 and is classed as GRAS (Generally Recognised As Safe) (Food and Drug Administration. 1988. Nisin preparation: Affirmation of GRAS status as a direct human ingredient. Federal Regulations 53: 11247). The international activity unit (IU hereinafter) was defined as 0.001 mg of an international nisin reference preparation. 25 Nisaplin® Natural Antimicrobial is the brand name for a nisin concentrate containing 1 million IU per g, which is commercially available from Danisco.

Nisin is an acknowledged and accepted food preservative with a long history of safe, 25 effective food use. There have been several reviews of nisin, e.g. Hurst 1981; 1983; Delves-Broughton, 1990; De Vuyst and Vandamme, 1994; Thomas *et al.* 2000; Thomas & Delves-Broughton, 2001). Nisin was discovered over 50 years ago and the first 30 commercial preparation, made in 1953, was Nisaplin®. Nisin has several characteristics that make it particularly suitable as a food preservative. It has undergone extensive toxicological testing to demonstrate its safety. It is heat-stable, acid-stable and effective 35 against a broad spectrum of Gram-positive bacteria. It is not normally effective against Gram-negative bacteria, yeasts or moulds but activity against Gram-negative bacteria and yeasts has been reported in the presence of chelating agents (PCT/US 8902625. WO 89/12399). Nisin is an effective preservative in pasteurised and heat-treated foods (e.g. processed cheese, cheese, pasteurised milks, dairy desserts, cream, mascarpone 35 and other dairy products, puddings such as semolina, tapioca etc., pasteurised liquid

egg, pasteurised potato products, soy products, crumpets, pikelets, flapjacks, processed meat products, beverages, soups, sauces, ready to eat meals, canned foods, vegetable drinks) and low acid foods such as salad dressings, sauces, mayonnaise, beer, wine and other beverages.

5

Although some loss of activity may be expected when used with processed foods, this may be ameliorated e.g. by increasing the amount of nisin applied. Effective levels of nisin to preserve foodstuffs reportedly range from 25-500 IU/g or more. Other effective levels would be appreciated by one skilled in the art. For example levels of 50-400 IU/g
10 may be utilised.

Since the discovery of the first bacteriocin, nisin, many other bacteriocins have now been found (Hoover, 1993; Ray & Daeschel, 1994; Axelsen, 1998; Naidu, 2000; Ray *et al.* 2001; Ray & Miller, 2003). The bacteriocin pediocin, produced by *Pediococcus pentosaceus*, *P. acidilactici*, or *Lactobacillus plantarum*, may be used in the present invention. Like nisin, different structures of pediocin have been described. At present pediocin and other bacteriocins are not allowed as food additives but their antibacterial activity can be achieved by production of the bacteriocin *in situ*, as a consequence of the growth of the producer organism in the food. This is the purpose of commercial
20 protective cultures such as HOLDBAC™ Listeria (Danisco). Pediocin has a more narrow antimicrobial spectrum compared to nisin, but there is much interest in its food safety ability to kill, prevent or control the growth of the food pathogen *Listeria monocytogenes* (Ray & Miller, 2000). Other bacteriocins may be used in the present invention, including those named generally as divercin, leucocin, mesentericin, sakacin, curvacin, bavaricin,
25 acidocin, bifidocin, carnobacteriocin, pisicocin, piscicolin, mundticin, enterocin, thermophilin, lacticin, plantaricin, lactococcin, dricin, diplococcin, mesenterocin, leuconosin, carnosin, acidophilin, lactacin, brevicin, lactocin, helevticin, reutericin, propionicin.

30 **EXTRACT**

As discussed herein when the antimicrobial material consists of nisin, the composition comprises carvacrol in an amount of less than 0.075wt.% based on the composition and carvone in an amount of less than 15wt.% based on the composition.

In one preferred aspect when the antimicrobial material consists of nisin, the composition comprises carvacrol in an amount of less than 0.05wt.% based on the composition, preferably less than 0.04wt.%, preferably less than 0.02wt.%, preferably less than 0.01wt.%, based on the composition.

5

In one preferred aspect, the composition comprises carvacrol in an amount of less than 0.05wt.% based on the composition, preferably less than 0.04wt.%, preferably less than 0.02wt.%, preferably less than 0.01wt.%, based on the composition.

- 10 In one preferred aspect when the antimicrobial material consists of nisin, the composition comprises carvone in an amount of less than 10wt.% based on the composition, preferably less than 7wt.%, preferably less than 5wt.%, preferably less than 2wt.%, preferably less than 1wt.%, preferably less than 0.75wt.%, preferably less than 0.5wt.%, preferably less than 0.2wt.%, preferably less than 0.1wt.%, preferably less than 0.075wt.%, preferably less than 0.05wt.%, preferably less than 0.04wt.%, preferably less than 0.02wt.%, preferably less than 0.01wt.%, based on the composition.
- 15

- 20 In one preferred aspect the composition comprises carvone in an amount of less than 10wt.% based on the composition, preferably less than 7wt.%, preferably less than 5wt.%, preferably less than 2wt.%, preferably less than 1wt.%, preferably less than 0.75wt.%, preferably less than 0.5wt.%, preferably less than 0.2wt.%, preferably less than 0.1wt.%, preferably less than 0.075wt.%, preferably less than 0.05wt.%, preferably less than 0.04wt.%, preferably less than 0.02wt.%, preferably less than 0.01wt.%, based on the composition.
- 25

- 30 In one preferred aspect when the antimicrobial material consists of nisin, the composition comprises thymol in an amount of less than 15wt.% based on the composition, preferably less than 10wt.%, preferably less than 7wt.%, preferably less than 5wt.%, preferably less than 2wt.%, preferably less than 1wt.%, preferably less than 0.75wt.%, preferably less than 0.5wt.%, preferably less than 0.2wt.%, preferably less than 0.1wt.%, preferably less than 0.075wt.%, preferably less than 0.05wt.%, preferably less than 0.04wt.%, preferably less than 0.02wt.%, preferably less than 0.01wt.%, based on the composition.
- 35 In one preferred aspect the composition comprises thymol in an amount of less than

15wt.% based on the composition preferably less than 10wt.%, preferably less than 7wt.%, preferably less than 5wt.%, preferably less than 2wt.%, preferably less than 1wt.%, preferably less than 0.75wt.%, preferably less than 0.5wt.%, preferably less than 0.2wt.%, preferably less than 0.1wt.%, preferably less than 0.075wt.%, preferably less than 0.05wt.%, preferably less than 0.04wt.%, preferably less than 0.02wt.%, preferably less than 0.01wt.%, based on the composition.

10 In one preferred aspect when the antimicrobial material consists of nisin, the composition comprises eugenol in an amount of less than 15wt.% based on the composition, preferably less than 10wt.%, preferably less than 7wt.%, preferably less than 5wt.%, preferably less than 2wt.%, preferably less than 1wt.%, preferably less than 0.75wt.%, preferably less than 0.5wt.%, preferably less than 0.2wt.%, preferably less than 0.1wt.%, preferably less than 0.075wt.%, preferably less than 0.05wt.%, preferably less than 0.04wt.%, preferably less than 0.02wt.%, preferably less than 0.01wt.%, based on the composition.

15 20 In one preferred aspect the composition comprises eugenol in an amount of less than 15wt.% based on the composition preferably less than 10wt.%, preferably less than 7wt.%, preferably less than 5wt.%, preferably less than 2wt.%, preferably less than 1wt.%, preferably less than 0.75wt.%, preferably less than 0.5wt.%, preferably less than 0.2wt.%, preferably less than 0.1wt.%, preferably less than 0.075wt.%, preferably less than 0.05wt.%, preferably less than 0.04wt.%, preferably less than 0.02wt.%, preferably less than 0.01wt.%, based on the composition.

25 In one preferred aspect when the antimicrobial material consists of nisin, the composition comprises carvacrol in an amount of less than 0.075wt.% based on the composition and each of carvone and thymol in amounts of less than 15wt.% based on the composition (preferably less than 10wt.% based on the composition, preferably less than 7wt.%, preferably less than 5wt.%, preferably less than 2wt.%, preferably less than 1wt.%, preferably less than 0.75wt.%, preferably less than 0.5wt.%, preferably less than 0.2wt.%, preferably less than 0.1wt.%, preferably less than 0.075wt.%, preferably less than 0.05wt.%, preferably less than 0.04wt.%, preferably less than 0.02wt.%, preferably less than 0.01wt.%, based on the composition):

30 35 In one preferred aspect, the composition comprises carvacrol in an amount of less than

0.075wt.% based on the composition and each of carvone and thymol in amounts of less than 15wt.% based on the composition (preferably less than 10wt.% based on the composition, preferably less than 7wt.%, preferably less than 5wt.%, preferably less than 2wt.%, preferably less than 1wt.%, preferably less than 0.75wt.%, preferably less than 5wt.%, preferably less than 0.5wt.%, preferably less than 0.2wt.%, preferably less than 0.1wt.%, preferably less than 0.075wt.%, preferably less than 0.05wt.%, preferably less than 0.04wt.%, preferably less than 0.02wt.%, preferably less than 0.01wt.%, based on the composition).

In one preferred aspect when the antimicrobial material consists of nisin, the composition

10 comprises carvacrol in an amount of less than 0.075wt.% based on the composition and each of carvone, thymol and eugenol in amounts of less than 15wt.% based on the composition (preferably less than 10wt.% based on the composition, preferably less than 7wt.%, preferably less than 5wt.%, preferably less than 2wt.%, preferably less than 1wt.%, preferably less than 0.75wt.%, preferably less than 0.5wt.%, preferably less than 0.2wt.%, preferably less than 0.1wt.%, preferably less than 0.075wt.%, preferably less than 0.05wt.%, preferably less than 0.04wt.%, preferably less than 0.02wt.%, preferably less than 0.01wt.%, based on the composition).

In one preferred aspect, the composition comprises carvacrol in an amount of less than 0.075wt.% based on the composition and each of carvone, thymol and eugenol in amounts of less than 15wt.% based on the composition (preferably less than 10wt.% based on the composition, preferably less than 7wt.%, preferably less than 5wt.%, preferably less than 2wt.%, preferably less than 1wt.%, preferably less than 0.75wt.%, preferably less than 0.5wt.%, preferably less than 0.2wt.%, preferably less than 0.1wt.%, preferably less than 0.075wt.%, preferably less than 0.05wt.%, preferably less than 0.04wt.%, preferably less than 0.02wt.%, preferably less than 0.01wt.%, based on the composition).

In one preferred aspect when the antimicrobial material consists of nisin, the composition

30 comprises each of carvacrol and carvone in an amount of less than 1wt.% based on the extract. Preferably when the antimicrobial material consists of nisin the composition comprises each of carvacrol and carvone in an amount of less than 0.075wt.%, preferably less than 0.05wt.%, preferably less than 0.04wt.%, preferably less than 0.02wt.%, preferably less than 0.01wt.%, based on the extract.

In one preferred aspect when the antimicrobial material consists of nisin, the composition comprises each of carvacrol, carvone and thymol in amounts of less than 1wt.% based on the extract. Preferably when the antimicrobial material consists of nisin the composition comprises each of carvacrol, carvone and thymol in an amount of less than 5 0.075wt.%, preferably less than 0.05wt.%, preferably less than 0.04wt.%, preferably less than 0.02wt.%, preferably less than 0.01wt.%, based on the extract.

In one preferred aspect when the antimicrobial material consists of nisin, the composition comprises each of carvacrol, carvone, thymol and eugenol in amounts of less than 1wt.% 10 based on the extract. Preferably when the antimicrobial material consists of nisin the composition comprises each of carvacrol, carvone, thymol and eugenol in an amount of less than 0.075wt.%, preferably less than 0.05wt.%, preferably less than 0.04wt.%, preferably less than 0.02wt.%, preferably less than 0.01wt.%, based on the extract.

15 In one preferred aspect the composition comprises each of carvacrol and carvone in an amount of less than 1wt.% based on the extract. Preferably the composition comprises each of carvacrol and carvone in an amount of less than 0.075wt.%, preferably less than 0.05wt.%, preferably less than 0.04wt.%, preferably less than 0.02wt.%, preferably less than 0.01wt.%, based on the extract.

20 In one preferred aspect the composition comprises each of carvacrol, carvone and thymol in amounts of less than 1wt.% based on the extract. Preferably the composition comprises each of carvacrol, carvone and thymol in an amount of less than 0.075wt.%, preferably less than 0.05wt.%, preferably less than 0.04wt.%, preferably less than 25 0.02wt.%, preferably less than 0.01wt.%, based on the extract.

In one preferred aspect the composition comprises each of carvacrol, carvone, thymol and eugenol in amounts of less than 1wt.% based on the extract. Preferably the composition comprises each of carvacrol, carvone, thymol and eugenol in an amount of 30 less than 0.075wt.%, preferably less than 0.05wt.%, preferably less than 0.04wt.%, preferably less than 0.02wt.%, preferably less than 0.01wt.%, based on the extract.

The extract used in the present invention is obtained from or is obtainable from a plant of the Labiatae family.

In one aspect the extract used in the present invention is obtained from a plant of the Labiatae family.

It will be appreciated by one skilled in the art that by the term "extract" or "extracts" it is
5 meant any constituent of the plant which may be isolated from the whole plant.

In one aspect the extract used in the present invention is obtainable from a plant of the Labiatae family. It will be appreciated by one skilled in the art that an extract obtainable from a plant may be obtained from a plant or may be isolated from the plant, identified
10 and then obtained from an alternative source, for example by chemical synthesis or enzymatic production. For example the extract may be produced by a eukaryotic or prokaryotic fermentation, by a process of genetic manipulation. The present applicant have recognised that products present in a plant of the Labiatae family may synergistically increase the activity of a antimicrobial material, preferably a
15 bacteriocin. These products may be obtained from any source and will fall within the scope of the present invention.

The invention comprises use of a combination of a bacteriocin such as nisin and a of the Labiatae plant family, such as rosemary (*Rosmarinus officinalis*) or sage (*Salvia officinalis*) that together give enhanced control of Gram-positive bacteria in a food system. The extracts responsible for synergy in the present invention preferably refer to extracts of the plant family Labiatae that have been selectively extracted ("deodorised extracts") to increase their phenolic diterpene content (such as carnosol and carnosic acid), phenolic tripterpane content (such as ursolic acid, betulinic acid and oleanolic acid)
25 or rosmarinic acid content. These deodorised extracts can be distinguished by their high phenolic diterpene content (for example greater than 3.5 wt.%) and their low level (less than 1 wt.%) of flavour-inducing compounds from plant essential oils and oleoresins that are used as flavours or fragrances. Essential oils are typically extracted by simple steam distillation of the plant material.

30 Essential oils comprise the various essential oils in plants having the odour or the flavour of the plant from which they were extracted. The essential oils are typically terpenoids often comprising monoterpenes. For example an antioxidant type of rosemary extract, which could be described as selectively extracted or deodorised, contains > 3.5% phenolic diterpenes but less than 1 wt.% essential oils. A non-selective, flavouring

extract contains 10–30 wt.% essential oils and a phenolic diterpene content of 2->3.5wt.%.

An essential oil is commonly described as the volatile ethereal fraction obtained from a 5 plant or plant part by a physical separation process such as distillation or chromatographic separation. Essential oils have also been described as a "group of odorous principles, soluble in alcohol and to a limited extent in water, consisting of a mixtures of esters, aldehydes, ketones and terpenes. Essential oils are typically obtained by distilling plants with water; the oil that separates from distillate usually has 10 highly characteristic odors identified with the plant origin. The resulting mixture of organic compounds was thought, in the days of alchemists, to be the essence of the plant, hence the term "essential oil".

In one preferred aspect the extract is a deodorised extract. Preferably the (deodorised) 15 extract contains from 1.0 to 70 wt.% phenolic diterpenes, preferably 3.5 to 70 wt.% phenolic diterpenes and less than 1 wt.% essential oil.

In one preferred aspect the extract is selected from phenolic diterpenes, phenolic triterpenes and rosmarinic acid.

20 In one preferred aspect the extract is or comprises a phenolic diterpene. Preferably the phenolic diterpene is selected from carnosic acid, carnosol and methylcarnosic acid. Preferably the phenolic diterpene is selected from carnosic acid and carnosol.

25 In one preferred aspect the combined amount of phenolic diterpenes, and phenolic triterpenes and rosmarinic acid, based on the extract, is greater than 1.0 wt.%. In one preferred aspect the combined amount of phenolic diterpenes, and phenolic triterpenes and rosmarinic acid, based on the composition, is greater than 1.0 wt.%.

30 In one preferred aspect the combined amount of phenolic diterpenes, and phenolic triterpenes and rosmarinic acid, based on the extract, is greater than 3.5 wt.%. In one preferred aspect the combined amount of phenolic diterpenes, and phenolic triterpenes and rosmarinic acid, based on the composition, is greater than 3.5 wt.%.

35 In one preferred aspect the amount of phenolic diterpenes, based on the extract, is

greater than 1.0 wt.%. In one preferred aspect the amount of phenolic diterpenes, based on the composition, is greater than 1.0 wt.%.

5 In one preferred aspect the amount of phenolic diterpenes, based on the extract, is greater than 3.5 wt.%. In one preferred aspect the amount of phenolic diterpenes, based on the composition, is greater than 3.5 wt.%.

10 In one preferred aspect the amount of phenolic diterpenes, based on the composition, is greater than 1.0 wt.%, preferably greater than 2.0 wt.%, preferably greater than 3.0 wt.%, preferably greater than 3.5 wt.%, preferably greater than 5.0 wt.%, preferably greater than 10.0 wt.%, preferably greater than 20.0 wt.%, preferably greater than 40.0 wt.%, preferably greater than 50.0 wt.%.

15 In one preferred aspect the amount of phenolic diterpenes, based on the extract, is greater than 1.0 wt.%, preferably greater than 2.0 wt.%, preferably greater than 3.0 wt.%, preferably greater than 3.5 wt.%, preferably greater than 5.0 wt.%, preferably greater than 10.0 wt.%, preferably greater than 20.0 wt.%, preferably greater than 40.0 wt.%, preferably greater than 50.0 wt.%.

20 In one highly preferred aspect the extract contains one or more phenolic triterpenes. Preferably the phenolic triterpenes are selected from betulinic acid, oleanolic acid, and ursolic acid.

25 In one preferred aspect is or comprises a phenolic triterpene. Preferably the phenolic triterpene is selected from betulinic acid, oleanolic acid, and ursolic acid.

30 In one highly preferred aspect the amount of phenolic triterpenes, based on the extract, is greater than 3.5 wt.%. In one highly preferred aspect the amount of phenolic triterpenes, based on the composition, is greater than 3.5 wt.%.

In one preferred aspect the extract is or comprises rosmarinic acid.

35 In one preferred aspect the amount of rosmarinic acid, based on the extract, is greater than 3.5 wt.%. In one preferred aspect the amount of rosmarinic acid, based on the composition, is greater than 3.5 wt.%.

In one preferred aspect the extract contains flavour-inducing compounds and/or essential oils in an amount of less than 1 wt.% based on the extract. In one preferred aspect the extract contains flavour-inducing compounds and/or essential oils in an amount of less
5 than 1 wt.% based on the composition.

In one preferred aspect the extract contain less than 1 wt.% of plant essential oils and/or oleoresins based on the extract. In one preferred aspect the extract contain less than 1 wt.% of plant essential oils and/or oleoresins based on the composition.

10 In one preferred aspect the extract contains essential oils in an amount of less than 1 wt.% based on the extract. In one preferred aspect the extract contains essential oils in an amount of less than 1 wt.% based on the composition.

15 In one preferred aspect the plant of the Labiatae family is selected from rosemary, sage, oregano, marjoram, mint, balm, savoury and thyme. In one preferred aspect the plant of the Labiatae family is selected from rosemary, sage, oregano, marjoram, mint, balm, and savoury. It will be understood that these name cover all species and varieties of plants known by these names.

20 In one preferred aspect the plant of the Labiatae family is selected from rosemary (*Rosmarinus officinalis* L.), sage (*Salvia officinalis* L.) oregano (*Origanum vulgare* L.), marjoram (*Origanum marjorana* L.), mint (*Mentha* spp.), balm (*Melissa officinalis* L.), savoury (*Satureia hortensis*), thyme (*Thymus vulgaris* L.).

25 In one preferred aspect the plant of the Labiatae family is selected from rosemary (*Rosmarinus officinalis* L.), sage (*Salvia officinalis* L.) oregano (*Origanum vulgare* L.), marjoram (*Origanum marjorana* L.), mint (*Mentha* spp.), balm (*Melissa officinalis* L.), and savoury (*Satureia hortensis*).

30 In one preferred aspect the plant of the Labiatae family is rosemary.

In a further preferred aspect the phenolic diterpenes, phenolic triterpenes and rosmarinic acid are obtained by chemical synthesis.

Thus in highly preferred aspects the present invention provides

- a composition comprising (a) an antimicrobial material and (b) a compound selected from carnosic acid, carnosol, methylcarnosic acid, betulinic acid, oleanolic acid, ursolic acid and rosmarinic acid (preferably carnosic acid and carnosol).
- a process for preventing and/or inhibiting the growth of, and/or killing a micro-organism in a material, the process comprising the step of contacting the material with (a) a bacteriocin; and (b) a compound selected from carnosic acid, carnosol, methylcarnosic acid, betulinic acid, oleanolic acid, ursolic acid and rosmarinic acid (preferably carnosic acid and carnosol).
- use of (a) an antimicrobial material and (b) a compound selected from carnosic acid, carnosol, methylcarnosic acid, betulinic acid, oleanolic acid, ursolic acid and rosmarinic acid (preferably carnosic acid and carnosol), for preventing and/or inhibiting the growth of, and/or killing a micro-organism in a material.

MICROORGANISM

As discussed herein the present invention may prevent and/or inhibit the growth of, and/or kill a micro-organism in a material. This may be slowing or arresting a micro-organism, such a bacteria, or by killing the micro-organism present on contact with the present composition.

In one aspect the antimicrobial material and/or the extract are present in an amount to provide a microbicidal or microbiostatic effect.

In one aspect the bacteriocin and the extract are present in an amount to provide a microbicidal or microbiostatic effect.

30 In one aspect the bacteriocin and the extract are present in an amount to provide a microbicidal or microbiostatic synergistic effect.

In one aspect the bacteriocin and the extract are present in an amount to provide a microbicidal synergistic effect.

In a highly preferred aspect the microbicidal or microbiostatic effect is a bactericidal or bacteriostatic effect.

It is advantageous for the bactericidal or bacteriostatic effect to be in respect of Gram-
5 positive bacteria and Gram-negative bacteria. Preferably the bactericidal or bacteriostatic effect is in respect of Gram-positive bacteria.

In a preferred aspect the bactericidal or bacteriostatic effect is in respect of an organism selected from Gram-positive bacteria associated with food spoilage or foodborne disease
10 including *Bacillus* species, *Bacillus subtilis*, *Bacillus cereus*, *Listeria* species, *Listeria monocytogenes*, lactic acid bacteria, lactic acid spoilage bacteria, *Lactobacillus* species, *Staphylococcus aureus*, *Clostridium* species, *C. sporogenes*, *C. tyrobutyricum*.

In a preferred aspect the bactericidal or bacteriostatic effect of the invention in
15 combination with a chelating agent is in respect of an organism selected from other micro-organisms associated with food spoilage or foodborne disease, including yeasts, moulds and Gram-negative bacteria including *Escherichia coli*, *Salmonella* species, and *Pseudomonas* species.

20 In a preferred aspect the bactericidal or bacteriostatic effect is in respect of an organism selected from *Bacillus cereus* 204, *B. cereus* Campden, *B. cereus* NCTC2599, *B. subtilis* Campden, *Clostridium sporogenes* strain Campden, *Clostridium sporogenes* strain 1.221, *Clostridium sporogenes* NCIMB1793, *Listeria monocytogenes* 272, *L. monocytogenes* NCTC12426, *L. monocytogenes* S23, *Lactobacillus sake* 272,
25 *Escherichia coli* S15, *E. coli* CRA109, *Salmonella* Typhimurium S29, *Pseudomonas fluorescens* 3756,

In a preferred aspect the bactericidal or bacteriostatic effect is in respect of *Listeria monocytogenes*.

30

FOODSTUFF

The composition, process and use of the present invention may prevent and/or inhibit the growth of, and/or kill a micro-organism in any material. However, in view of the problems
35 associated with spoilage and contamination of foodstuffs and in view of the particular

effectiveness of the present invention in foodstuffs, preferably the composition is a foodstuff or may be added to a foodstuff. It will be appreciated by one skilled in the art that when the present composition is a foodstuff the essential components of (a) an antimicrobial material and (b) a extract obtained from or obtainable from a plant of the 5 Labiatae family are already present in the foodstuff. They may have been provided by one or more means. For example they may have been added in the form of a composition containing the bacteriocin and the extract. The two components (the bacteriocin and the afore mentioned extract) may have been added to the foodstuff sequentially. In one further aspect one or more of the components may have been formed 10 *in situ* in the foodstuff. For example the bacteriocin may be formed *in situ* in the foodstuff by fermentation of the dairy starter culture bacterium *Lactococcus lactis* subsp. *lactis*.

In one aspect the composition of the present invention is a protectant composition suitable for addition to a foodstuff.

15 Many foodstuffs may be protected by the present invention. Typical foodstuffs are raw meat, cooked meat, raw poultry products, cooked poultry products, raw seafood products, cooked seafood products, ready to eat meals, pasta sauces, pasteurised soups, mayonnaise, salad dressings, oil-in-water emulsions, margarines, low fat 20 spreads, water-in-oil emulsions, dairy products, cheese spreads, processed cheese, dairy desserts, flavoured milks, cream, fermented milk products, cheese, butter, condensed milk products, ice cream mixes, soya products, pasteurised liquid egg, bakery products, confectionery products, fruit products, and foods with fat-based or water-containing fillings.

25

ADDITIONAL COMPONENTS

The composition of the present invention or the composition for use in the present invention may contain one or more additional components. However, in some aspects 30 the protectant composition of the present invention (suitable for addition to a foodstuff) contains no additional components or contains no additional components that materially affect the properties of the composition. In these aspects the present invention provides

- a composition consisting essentially of (a) a bacteriocin and (b) an extract obtained from or obtainable from a plant of the Labiatae family, wherein (a) and (b) are 35 different

- a composition consisting of (a) a bacteriocin and (b) an extract obtained from or obtainable from a plant of the Labiatae family, wherein (a) and (b) are different
- a composition consisting essentially of (a) a bacteriocin and (b) an extract obtained from or obtainable from a plant of the Labiatae family, wherein (a) and (b) are different, wherein when the antimicrobial material consists of nisin, the composition comprises carvacrol in an amount of less than 0.075wt.% based on the composition and carvone in an amount of less than 15wt.% based on the composition.
- a composition consisting of (a) a bacteriocin and (b) an extract obtained from or obtainable from a plant of the Labiatae family, wherein (a) and (b) are different, wherein when the antimicrobial material consists of nisin, the composition comprises carvacrol in an amount of less than 0.075wt.% based on the composition and carvone in an amount of less than 15wt.% based on the composition.

15 In one preferred aspect the composition further comprises an emulsifier. Preferably the emulsifier is selected from polyoxy-ethylene sorbitan esters (E432-E436) otherwise known as polysorbates (e.g. Tween 80, Tween 20), monoglycerides, diglycerides, acetic acid esters of mono-diglycerides, tartaric acid esters of mono-diglycerides and citric acid esters of mono-diglycerides.

20 In one preferred aspect the composition further comprises a chelator. Preferably the chelator is selected from EDTA, citric acid, monophosphates, diphosphates, triphosphates and polyphosphates.

25 Further suitable chelator are taught in US 5573801 and include carboxylic acids, polycarboxylic acids, amino acids and phosphates. In particular, the following compounds and their salts may be useful:

30 Acetic acid, Adenine, Adipic acid, ADP, Alanine, B-Alanine, Albumin, Arginine, Ascorbic acid, Asparagine, Aspartic acid, ATP, Benzoic acid, n-Butyric acid, Casein, Citraconic acid, Citric acid, Cysteine, Dehydracetic acid, Desferri-ferrichrysin, Desferri-ferrichrome, Desferri-ferrioxamin E, 3,4-Dihydroxybenzoic acid, Diethylenetriaminepentaacetic acid (DTPA), Dimethylglyoxime, O,O-Dimethylpurpurogallin, EDTA, Formic acid, Fumaric acid, Globulin, Gluconic acid, Glutamic acid, Glutaric acid, Glycine, Glycolic acid, Glycylglycine, Glycylsarcosine, Guanosine, Histamine, Histidine, 3-Hydroxyflavone, 35 Inosine, Inosine triphosphate, Iron-free ferrichrome, Isovaleric acid, Itaconic acid, Kojic

acid, Lactic acid, Leucine, Lysine, Maleic acid, Malic acid, Methionine, Methylsalicylate, Nitrilotriacetic acid (NTA), Ornithine, Orthophosphate, Oxalic acid, Oxystearin, B-Phenylalanine, Phosphoric acid, Phytate, Pimelic acid, Pivalic acid, Polyphosphate, Proline, Propionic acid, Purine, Pyrophosphate, Pyruvic acid, Riboflavin, Salicylaldehyde, 5 Salicyclic acid, Sarcosine, Serine, Sorbitol, Succinic acid, Tartaric acid, Tetrametaphosphate, Thiosulfate, Threonine, Trimetaphosphate, Triphosphate, Tryptophan, Uridine diphosphate, Uridine triphosphate, n-Valeric acid, Valine, and Xanthosine

10 Many of the above sequestering agents are useful in food processing in their salt forms, which are commonly alkali metal or alkaline earth salts such as sodium, potassium or calcium or quaternary ammonium salts. Sequestering compounds with multiple valencies may be beneficially utilised to adjust pH or selectively introduce or abstract metal ions e.g. in a food system coating. Additional information chelators is disclosed in

15 T. E. Furia (Ed.), CRC Handbook of Food Additives, 2nd Ed., pp. 271-294 (1972, Chemical Rubber Co.), and M. S. Peterson and A. M. Johnson (Eds.), Encyclopaedia of Food Science, pp. 694-699 (1978, AVI Publishing Company, Inc.) which articles are both hereby incorporated by reference.

20 The terms " chelator" is defined as organic or inorganic compounds capable of forming co-ordination complexes with metals. Also, as the term " chelator" is used herein, it includes molecular encapsulating compounds such as cyclodextrin. The chelator may be inorganic or organic, but preferably is organic.

25 Preferred chelator are non-toxic to mammals and include aminopolycarboxylic acids and their salts such as ethylenediaminetetraacetic acid (EDTA) or its salts (particularly its di- and tri-sodium salts), and hydrocarboxylic acids and their salts such as citric acid. However, non-citric acid and non-citrate hydrocarboxylic acid chelators are also believed useful in the present invention such as acetic acid, formic acid, lactic acid, tartaric acid 30 and their salts.

As noted above, the term " chelator" is defined and used herein as a synonym for sequestering agent and is also defined as including molecular encapsulating compounds such as cyclodextrin. Cyclodextrins are cyclic carbohydrate molecules having six, seven, 35 or eight glucose monomers arranged in a donut shaped ring, which are denoted alpha,

beta or gamma cyclodextrin, respectively. As used herein, cyclodextrin refers to both unmodified and modified cyclodextrin monomers and polymers. Cyclodextrin molecular encapsulators are commercially available from American Maize-Products of Hammond, Ind. Cyclodextrin are further described in Chapter 11 entitled, "Industrial Applications of 5 Cyclodextrin", by J. Szejtli, page 331-390 of Inclusion Compounds, Vol. III (Academic Press, 1984) which chapter is hereby incorporated by reference.

Preferably the chelator enhances the antimicrobial activity and/or antimicrobial spectrum of the bacteriocin. More preferably the chelator enhances the antimicrobial activity 10 and/or antimicrobial spectrum of the bacteriocin in respect of Gram-negative bacteria and other micro-organisms.

In one preferred aspect the composition further comprises a lytic enzyme. Preferably the lytic enzyme is a lysozyme.

15

PROCESS

As discussed herein in one aspect the present invention provides process for preventing and/or inhibiting the growth of, and/or killing a micro-organism in a material, the process 20 comprising the step of contacting the material with (a) an antimicrobial material; and (b) an extract obtained from or obtainable from a plant of the Labiatae family, wherein (a) and (b) are different; wherein when the antimicrobial material consists of nisin, the composition comprises carvacrol in an amount of less than 0.075wt.% based on the composition and carvone in an amount of less than 15wt.% based on the composition.

25

In one aspect the bacteriocin and the extract are added to the material together.

In one aspect the bacteriocin and the extract are added to the material sequentially.

30 Thus the present invention provides in one aspect a preservative/protectant composition which may be added to a range of materials such as food systems and in another aspect a combination of two separate products which may be added sequentially to materials such as food products.

35 In one aspect the extract is added to the material.

In one aspect the bacteriocin is added to the material.

In one aspect the extract is formed *in situ* in the material.

5

In one aspect the bacteriocin is formed *in situ* in the material. Preferably when the bacteriocin is nisin, the bacteriocin may be formed *in situ* in the foodstuff by fermentation of the dairy starter culture bacterium *Lactococcus lactis* subsp. *lactis*.

10 **HIGHLY PREFERRED ASPECTS**

As discussed herein in one aspect the present invention provides a process for preventing and/or inhibiting the growth of, and/or killing a micro-organism in a material, the process comprising the step of contacting the material with (a) an antimicrobial material;

15 and (b) an extract obtained from or obtainable from a plant of the Labiatae family, wherein (a) and (b) are different; wherein when the antimicrobial material consists of nisin, the composition comprises carvacrol in an amount of less than 0.075wt.% based on the composition and carvone in an amount of less than 15wt.% based on the composition.

20

In one aspect the present invention provides use of (a) an antimicrobial material; and b) an extract obtained from or obtainable from a plant of the Labiatae family, for preventing and/or inhibiting the growth of, and/or killing a micro-organism in a material; wherein (a) and (b) are different; and wherein when the antimicrobial material consists of nisin, the 25 composition comprises carvacrol in an amount of less than 0.075wt.% based on the composition and carvone in an amount of less than 15wt.% based on the composition.

Some highly preferred aspects of the present invention are set out below

30 • a composition comprising (a) a bacteriocin, wherein the bacteriocin is nisin; and (b) an extract obtained from a plant of the Labiatae family, wherein the composition comprises carvacrol in an amount of less than 0.075wt.% based on the composition and carvone in an amount of less than 15wt.% based on the composition.

35 • for preventing and/or inhibiting the growth of, and/or killing a micro-organism in a

material, the process comprising the step of contacting the material with (a) a bacteriocin; wherein the bacteriocin is nisin; and (b) an extract obtained from or obtainable from a plant of the Labiatae family, wherein the composition comprises carvacrol in an amount of less than 0.075wt.% based on the composition and carvone in an amount of less than 15wt.% based on the composition.

- 5 • use of (a) a bacteriocin, wherein the bacteriocin is nisin; and (b) an extract obtained from or obtainable from a plant of the Labiatae family, for preventing and/or inhibiting the growth of, and/or killing a micro-organism in a material, the composition comprises carvacrol in an amount of less than 0.075wt.% based on the composition and carvone in an amount of less than 15wt.% based on the composition.
- 10 • a composition comprising (a) a bacteriocin, and (b) an extract obtained from a plant of the Labiatae family selected from rosemary, sage, thyme, mint, balm, savoury and oregano, wherein (a) and (b) are different
- 15 • a process for preventing and/or inhibiting the growth of, and/or killing a micro-organism in a material, the process comprising the step of contacting the material with (a) a bacteriocin; and (b) an extract obtained from or obtainable from a plant of the Labiatae family selected from rosemary, sage, thyme, mint, balm, savoury and oregano, wherein (a) and (b) are different.
- 20 • use of (a) a bacteriocin, and (b) an extract obtained from or obtainable from a plant of the Labiatae family selected from rosemary, sage, thyme, mint, balm, savoury and oregano, for preventing and/or inhibiting the growth of, and/or killing a micro-organism in a material, wherein (a) and (b) are different
- 25 • a composition comprising (a) a bacteriocin, and (b) a compound selected from carnosic acid, carnosol, methylcarnosic acid, betulinic acid, oleanolic acid, ursolic acid and rosmarinic acid.
- 30 • a process for preventing and/or inhibiting the growth of, and/or killing a micro-organism in a material, the process comprising the step of contacting the material with (a) a bacteriocin, and (b) a compound selected from carnosic acid, carnosol, methylcarnosic acid, betulinic acid, oleanolic acid, ursolic acid and rosmarinic acid.

- use of (a) a bacteriocin, and (b) a compound selected from carnosic acid, carnosol, methylcarnosic acid, betulinic acid, oleanolic acid, ursolic acid and rosmarinic acid, for preventing and/or inhibiting the growth of, and/or killing a micro-organism in a material.

5

- a composition comprising (a) a bacteriocin, and (b) carnosic acid .
- a process for preventing and/or inhibiting the growth of, and/or killing a micro-organism in a material, the process comprising the step of contacting the material with (a) a bacteriocin, and (b) carnosic acid.

10

- use of (a) a bacteriocin, and (b) carnosic acid, for preventing and/or inhibiting the growth of, and/or killing a micro-organism in a material.

15

- a composition comprising (a) a bacteriocin, wherein the bacteriocin is nisin; and (b) an extract obtained from or obtainable from a plant of the Labiatae family selected from rosemary, thyme, mint, balm, savoury, sage and oregano, wherein the composition comprises carvacrol in an amount of less than 0.075wt.% based on the composition and carvone in an amount of less than 15wt.% based on the composition.

20

- a process for preventing and/or inhibiting the growth of, and/or killing a micro-organism in a material, the process comprising the step of contacting the material with (a) a bacteriocin; wherein the bacteriocin is nisin; and (b) a selectively extracted extract obtained from or obtainable from a plant of the Labiatae family selected from rosemary, sage, thyme, mint, balm, savoury and oregano, wherein the composition comprises carvacrol in an amount of less than 0.075wt.% based on the composition and carvone in an amount of less than 15wt.% based on the composition.

25

- use of (a) a bacteriocin, wherein the bacteriocin is nisin; and (b) a selectively extracted extract obtained from or obtainable from a plant of the Labiatae family selected from rosemary, sage, thyme, mint, balm, savoury and oregano, for preventing and/or inhibiting the growth of, and/or killing a micro-organism in a material, wherein the composition comprises carvacrol in an amount of less than 0.075wt.% based on the composition and carvone in an amount of less than 15wt.% based on the composition.

35

- a composition comprising (a) a bacteriocin, wherein the bacteriocin is nisin; and

(b) a compound selected from carnosic acid, carnosol, methylcarnosic acid, betulinic acid, oloanolic acid, ursolic acid and rosmarinic acid, wherein the composition comprises carvacrol in an amount of less than 0.075wt.% based on the composition and carvone in an amount of less than 15wt.% based on the composition.

5

- a process for preventing and/or inhibiting the growth of, and/or killing a micro-organism in a material, the process comprising the step of contacting the material with (a) a bacteriocin, wherein the bacteriocin is nisin; and (b) a compound selected from carnosic acid, carnosol, methylcarnosic acid, betulinic acid, oloanolic acid, ursolic acid and rosmarinic acid, wherein the composition comprises carvacrol in an amount of less than 0.075wt.% based on the composition and carvone in an amount of less than 15wt.% based on the composition.
- use of (a) a bacteriocin, wherein the bacteriocin is nisin; and (b) a compound selected from carnosic acid, carnosol, methylcarnosic acid, betulinic acid, oloanolic acid, ursolic acid and rosmarinic acid, for preventing and/or inhibiting the growth of, and/or killing a micro-organism in a material, wherein the composition comprises carvacrol in an amount of less than 0.075wt.% based on the composition and carvone in an amount of less than 15wt.% based on the composition.
- a composition comprising (a) a bacteriocin, wherein the bacteriocin is nisin; and (b) carnosic acid;
- a process for preventing and/or inhibiting the growth of, and/or killing a micro-organism in a material, the process comprising the step of contacting the material with (a) a bacteriocin, wherein the bacteriocin is nisin; and (b) carnosic acid.
- use of (a) a bacteriocin, wherein the bacteriocin is nisin; and (b) carnosic acid, for preventing and/or inhibiting the growth of, and/or killing a micro-organism in a material.

20

- a composition comprising (a) a bacteriocin, wherein the bacteriocin is nisin; and (b) an extract obtained from a plant of the Labiatae family selected from rosemary, sage, thyme, mint, balm, savoury and oregano, wherein the bacteriocin and the extract are present in an amount to provide a bactericidal or bacteriostatic synergistic effect, wherein the composition comprises carvacrol in

30

25

30

35

an amount of less than 0.075wt.% based on the composition and carvone in an amount of less than 15wt.% based on the composition.

- a process for preventing and/or inhibiting the growth of, and/or killing a micro-organism in a material, the process comprising the step of contacting the material with (a) a bacteriocin; wherein the bacteriocin is nisin; and (b) an extract obtained from or obtainable from a plant of the Labiatae family selected from rosemary, sage, thyme, mint, balm, savoury and oregano, wherein the bacteriocin and the extract are present in an amount to provide a bactericidal or bacteriostatic synergistic effect wherein the composition comprises carvacrol in an amount of less than 0.075wt.% based on the composition and carvone in an amount of less than 15wt.% based on the composition.
- use of (a) a bacteriocin, wherein the bacteriocin is nisin; and (b) an extract obtained from or obtainable from a plant of the Labiatae family selected from rosemary, sage, thyme, mint, balm, savoury and oregano, for preventing and/or inhibiting the growth of, and/or killing a micro-organism in a material, wherein the bacteriocin and the extract are present in an amount to provide a bactericidal or bacteriostatic synergistic effect, wherein the composition comprises carvacrol in an amount of less than 0.075wt.% based on the composition and carvone in an amount of less than 15wt.% based on the composition.

- a composition comprising (a) a bacteriocin, wherein the bacteriocin is nisin; and (b) a compound selected from carnosic acid, carnosol, methylcarnosic acid, betulinic acid, oleanolic acid, ursolic acid and rosmarinic acid, wherein the bacteriocin and the compound are present in an amount to provide a bactericidal or bacteriostatic synergistic effect wherein the composition comprises carvacrol in an amount of less than 0.075wt.% based on the composition and carvone in an amount of less than 15wt.% based on the composition.
- a process for preventing and/or inhibiting the growth of, and/or killing a micro-organism in a material, the process comprising the step of contacting the material with (a) a bacteriocin, wherein the bacteriocin is nisin; and (b) a compound selected from carnosic acid, carnosol, methylcarnosic acid, betulinic acid, oleanolic acid, ursolic acid and rosmarinic acid, wherein the bacteriocin and the compound are present in an amount to provide a bactericidal or bacteriostatic synergistic effect wherein the composition comprises carvacrol in an amount of less than 0.075wt.% based on the composition and carvone in an amount of less than 0.075wt.% based on the composition and carvone in an amount of less than 15wt.% based on the composition.

than 15wt.% based on the composition.

- use of (a) a bacteriocin, wherein the bacteriocin is nisin; and (b) a compound selected from carnosic acid, carnosol, methylcarnosic acid, betulinic acid, oleanolic acid, ursolic acid and rosmarinic acid, for preventing and/or inhibiting the growth of, and/or killing a micro-organism in a material, wherein the bacteriocin and the compound are present in an amount to provide a bactericidal or bacteriostatic synergistic effect wherein the composition comprises carvacrol in an amount of less than 0.075wt.% based on the composition and carvone in an amount of less than 15wt.% based on the composition.

10

- a composition comprising (a) a bacteriocin, wherein the bacteriocin is nisin; and (b) a compound selected from carnosic acid, wherein the bacteriocin and the compound are present in an amount to provide a bactericidal or bacteriostatic synergistic effect

15

- a process for preventing and/or inhibiting the growth of, and/or killing a micro-organism in a material, the process comprising the step of contacting the material with (a) a bacteriocin, wherein the bacteriocin is nisin; and (b) a compound selected from carnosic acid, wherein the bacteriocin and the compound are present in an amount to provide a bactericidal or bacteriostatic synergistic effect

20

- use of (a) a bacteriocin, wherein the bacteriocin is nisin; and (b) a compound selected from carnosic acid , for preventing and/or inhibiting the growth of, and/or killing a micro-organism in a material, wherein the bacteriocin and the compound are present in an amount to provide a bactericidal or bacteriostatic synergistic effect

25

The present invention will now be described in further detail by way of example only with reference to the accompanying figures in which:-

Figure 1 shows a graph;

30 Figure 2 shows a graph;

Figure 3 shows a graph;

Figure 4 shows a graph; and

Figure 5 shows a graph.

35 The present invention will now be described in further detail in the following examples.

EXAMPLES**Experimental evidence of benefit**

5

In vitro studies described herein have shown synergy between nisin and extracts of *Rosmarinus officinalis* containing > 3.5% phenolic diterpenes, increasing the efficacy of nisin significantly. This enhanced activity was also observed in food models, increasing nisin kill and growth control of Gram-positive bacteria. The experimental studies also 10 demonstrated that the phenolic diterpenes carnosic acid and carnosol were implicated in this synergy. The results also indicated that rosmarinic acid may also enhance nisin activity, although this synergistic effect was not as strong as that observed with the phenolic diterpenes.

15

I) *In vitro* demonstration of nisin and deodorised rosemary extract synergy

Materials: GUARDIAN™ Rosemary Extract 09 (Danisco) (GRE09). This is a water dispersible deodorised rosemary extract containing 4% phenolic diterpenes and < 1% essential oils, extracted from rosemary leaves, combined with the carriers 20 polyoxyethylene sorbitan monooleate (Tween 80) and propylene glycol. A commercial extract of nisin at potency of 1×10^6 IU/g: Nisaplin® Natural Antimicrobial (Danisco).

Test strains: *Bacillus cereus* 204, *B. cereus* Campden, *B. cereus* NCTC2599, *B. subtilis* Campden, *Listeria monocytogenes* 272, *L. monocytogenes* NCTC12426, *L. 25 monocytogenes* S23, *Lactobacillus sake* 272, *Escherichia coli* S15, *E. coli* CRA109, *Salmonella* Typhimurium S29, *Pseudomonas fluorescens* 3756.

Method of microbial growth curve analysis. A 100,000 ppm GRE09 solution was prepared in water and filter sterilised (0.2 μ m). Further dilutions were prepared in sterile 30 deionised water at 1,250 – 20,000 ppm. Brain Heart Infusion broth (Oxoid) was prepared and GRE09 stock solutions were added to give the following test solutions of GRE09; 125, 250, 500, 750, 1000, 1250, 1500, 2000 ppm. A 10,000 IU/ml nisin solution was prepared, filter sterilised and a range of stock solutions then prepared. A range of nisin concentrations was then prepared in Brain Heart Infusion broth. A fully automated 35 microbial growth analyser was used to determine microbial growth curves (Microbiology

Reader Bioscreen C analyser linked to a PC with installed software BioLink v 5.30; Labsystem Oy, Finland). Tests were prepared in honeycomb 2 (HC 2) microtitre/cuvette plates with a capacity of 100 wells per plate. The wells were loaded with 270 µl of the prepared media and inoculated at a level of 10^3 CFU(colony forming units)/ml with 30 µl of microbial suspension. Incubation time and temperature was as appropriate for the test organism. This test allowed suitable test levels for the compounds to be determined. The rosemary extract and nisin were then tested in combination, using the same procedure. Nisin solutions were prepared at 50 -1000 IU/ml in broth as above. GRE09 solutions were prepared at 250, 500 and 1000 ppm as above. Combinations of all these test levels were prepared and tested in the Bioscreen as before.

Results: The minimum inhibitory concentration of nisin alone, rosemary extract GRE09 alone and the two in combination in the Bioscreen after 48 h at 30 °C is shown in Table 1. The minimal inhibition was taken as the lowest concentration that caused total inhibition of the bacteria after 48 h at 30 °C. Synergy was observed between nisin and the rosemary extract GRE09 against all Gram-positive bacteria but no significant effect was observed against Gram-negative bacteria. This can be determined from the table by comparing the column of data showing MIC levels of nisin alone, GRE09 alone and the two combined. The latter column gave levels much lower than the other two for Gram-positive bacteria (*Bacillus*, *Listeria*) but not for Gram-negative bacteria (*E. coli*, *Salmonella*).

Table 1: Synergy tests of nisin and the rosemary extract GRE09

Test organism	MIC in broth after 48 h at 30 °C (total inhibition)			Other test levels of the combination causing total inhibition
	Nisin (IU/ml)	GRE09 (ppm)	MIC of nisin (IU/ml) +GRE09 (ppm)	
<i>B. cereus</i> 204	500	> 1000	50 + 250	50 + 500 50 + 1000 100 + 250 100 + 500 100 + 1000 200 + 250 200 + 500 200 + 1000
<i>B. cereus</i> NCTC2599	500	> 1000	50 + 250	50 + 500 50 + 1000 100 + 250 100 + 500 100 + 1000

Test organism	MIC in broth after 48 h at 30 °C (total inhibition)			Other test levels of the combination causing total inhibition
	Nisin (IU/ml)	GRE09 (ppm)	MIC of nisin (IU/ml) +GRE09 (ppm)	
				200 + 250 200 + 500 200 + 1000
<i>B. subtilis</i> Campden	100	> 1000	50 + 250	50 + 500 50 + 1000 100 + 250 100 + 500 100 + 1000 200 + 250 200 + 500 200 + 1000
<i>L. monocytogenes</i> S23	> 500	> 1000	50 + 250	50 + 500 50 + 1000 100 + 250 100 + 500 100 + 1000 200 + 250 200 + 500 200 + 1000
<i>L. monocytogenes</i> 272	> 500	> 1000	50 + 250	50 + 500 50 + 1000 100 + 250 100 + 500 100 + 1000 200 + 250 200 + 500 200 + 1000
<i>L. monocytogenes</i> 12426	> 500	> 1000	50 + 250	50 + 500 50 + 1000 100 + 250 100 + 500 100 + 1000 200 + 250 200 + 500 200 + 1000
<i>E. coli</i> S15	> 500	> 1000	> 1000 + > 1000	-
<i>E. coli</i> CRA109	> 500	> 1000	> 1000 + > 1000	-
<i>S. Typhimurium</i> S29	> 500	> 1000	> 1000 + > 1000	-
<i>Ps. fluorescens</i> 3756	> 500	> 1000	> 1000 + > 1000	-

II) Demonstration of nisin and rosemary extract GRE09 synergy in food

A) Synergy against *Listeria monocytogenes*

Test compounds: GRE09 at 0.1%, 0.5%, Nisaplin® (Danisco).

Test strains: a cocktail was prepared of *L. monocytogenes* strains NCTC12426, NCTC5105, NCC FSM60 and CRA3930. The *Listeria* strains were grown at 30 °C on Brain heart infusion agar overnight then inoculated into broth at 30 °C overnight. A volume of each broth was mixed together to give a cocktail of strains with a cell 5 concentration of approximately 10⁹ CFU/ml.

Media: A chilled pasteurised chicken soup was used as a food model because it was a good mix of different food components including vegetables, dairy products and poultry meat. It was comprised of a chicken stock with the addition of chicken, cream, 10 vegetables, flour and seasonings. The pH was 6.12. After addition of nisin and rosemary extract GRE09, the soup was pasteurised at a core temperature of 80 °C for 2 minutes. The *Listeria* cocktail was diluted to 10⁴ CFU/ml and inoculated into soup tests to give a final cell count of approximately 10² CFU/g (growth inhibitory tests) and 10⁷ CFU/ml 15 (cidal tests). The latter test was incubated at 25 °C for 2 h and then tested by viable count enumeration to estimate the extent ofcidal activity. The growth test was incubated at 8 °C with regular sampling to estimate bacteriostatic activity.

Results. The rosemary extract GRE09 alone at 0.5% showed no listericidal activity. Nisin at 250 IU/g caused a 1 log drop in *Listeria* numbers after 2 h, but only a slight delay 20 in growth after 24 h (Figure 1). In comparison the combination of the two test products at these levels caused a 2-3 log drop in *Listeria* numbers after 2 h. After 24 h the cells still had not recovered to their initial inoculum level. This was a particularly harsh test for any preservative system, since the test medium was a rich food model, the incubation temperature was at ambient and the bacterial numbers high. Therefore any enhanced 25 nisin activity was a good indication of synergy.

Incubation for the bacteriostatic test was for 43 days: results of this are shown in Figure 2 and Table 2. The nisin/rosemary synergy was again clearly demonstrated in the food model against the *Listeria* cocktail. For example, *Listeria* growth reached 10⁶ CFU/ml 30 after 13 days in the presence of 100 IU/ml nisin; after 10 days in the presence of 0.1% GRE09 but only after a much longer period, 34 days, in the presence of the combination of these two ingredients. Similarly, *Listeria* growth reached 10⁶ CFU/ml after 13 days in the presence of 100 IU/ml nisin; after 20 days in the presence of 0.5% GRE09. The combination of the two components resulted in no growth being observed by then end of 35 the test period.

Table 2. Summary of growth inhibition of Listeria in chilled chicken soup (Trial lasted 43 days)

Test conditions	Days until growth reached 10^6 CFU/ml
Control	6
Nisin at 100 IU/ml	13
Nisin at 250 IU/ml	27
Rosemary extract GRE09 at 0.1%	10
Rosemary extract GRE09 at 0.5%	20
Nisin (100 IU/ml) + GRE09 at 0.1%	34
Nisaplin (100 IU/ml) + GRE09 at 0.5%	> 43
Nisaplin (250 IU/ml) + GRE09 at 0.1%	> 43
Nisaplin (250 IU/ml) + GRE09 at 0.5%	> 43

5

During the test period (a) Nisaplin (100 IU/ml) + GRE09 at 0.5%, (b) Nisaplin (250 IU/ml) + GRE09 at 0.1%, and (c) Nisaplin (250 IU/ml) + GRE09 at 0.5% did not give any total aerobic viable counts above 100 cfu/g.

10 **B) Synergy against *Bacillus cereus***

Test strains: a cocktail of *Bacillus* spores was prepared as an inoculum, using *Bacillus cereus* strain 204, *Bacillus cereus* strain 199, *B. cereus* strain Campden, and *B. cereus* strain ABC 4/9.

15

Additions of the test compounds were made to chicken soup, prepared as above. The soup was pasteurised at 70 °C for 2 minutes, cooled and inoculated with approximately 10^3 CFU/g of a cocktail of *Bacillus cereus* spores. Incubation was for 56 days. Results are shown in Figure 3 and summarised in Table3. Bacteriostatic synergy between the 20 nisin and rosemary extract GRE09 was evident. For example, spoilage (i.e. 10^6 CFU/ml) resulted after 13 days in the presence of 25 IU/ml nisin, and after 10 days in the presence of 300 ppm GRE09. In the presence of both these ingredients, no spoilage had occurred by the end of the trial (56 days).

Table 3. Summary of results of chilled chicken soup trial inoculated with *Bacillus cereus* spores (Trial lasted 70 days).

Test conditions	Days until growth reached 10^6 CFU/ml
Control	6
Nisin at 25 IU/ml	13
Rosemary extract GRE09 at 300 ppm	10
Rosemary extract GRE09 at 600 ppm	13
Nisin (25 IU/ml) + GRE09 at 300 ppm	> 70
Nisaplin (25 IU/ml) + GRE09 at 600 ppm	> 70

5 C) Synergy against *Clostridium sporogenes*

Test strains: a cocktail of *Clostridium* spores was prepared as an inoculum, using *Clostridium sporogenes* strain Campden, *Clostridium sporogenes* 1.221, and *Clostridium sporogenes* NCIMB1793.

10

Additions of the test compounds were made to chicken soup, prepared as above. The soup was pasteurised at 70 °C for 2 minutes and transferred to sterile test tubes. These were inoculated with a cocktail of heat-shocked *Clostridium sporogenes* spores, at a level of 2.2×10^2 CFU/g, then anaerobic conditions were created by plugging the tubes 15 with agar. The samples were incubated at 37 °C and checked daily for gas production (observed by blowing of the gas plug and by the distinctive clostridial odour). Results for a 27 day incubation period, demonstrating synergy, are shown in Table 4. For example, synergy was clearly seen by the combined effect of 50 IU/ml nisin and 300 ppm GRE09, which prevented growth for 27 days (the length of the trial), whereas the individual 20 ingredients both prevented clostridial growth for 2 days (the same as the control).

Table 4. Summary of results of chicken soup trial inoculated with *Clostridium sporogenes* spores incubated at 37 °C (Trial lasted 27 days).

Test conditions	Days until growth observed (gas production)
Control	2
Nisin at 25 IU/ml	2
Nisin at 50 IU/ml	2
Nisin at 100 IU/ml	7
Rosemary extract GRE 09 at 300 ppm	2
Rosemary extract GRE 09 at 600 ppm	2
Nisin (25 IU/ml) + GRE 09 at 300 ppm	3

Test conditions	Days until growth observed (gas production)
Nisin (50 IU/ml) + GRE 09 at 300 ppm	> 27
Nisin (100 IU/ml) + GRE 09 at 300 ppm	> 27
Nisaplin (25 IU/ml) + GRE 09 at 600 ppm	10
Nisaplin (100 IU/ml) + GRE 09 at 600 ppm	> 27

III) Demonstration of *in vitro* synergy with different deodorised, selectively extracted rosemary extracts and rosmarinic acid

5 Growth curves of *Listeria monocytogenes* and *B. cereus* strains in laboratory media were analysed as described above using the Bioscreen C analyser. Minimal inhibitory concentrations (MIC) were determined for the test compounds used singly or in combination after 24 h at 30 °C. Results are shown in Table 5. The test compounds comprised nisin (as Nisaplin®; Danisco), GRE09 (Danisco), pure rosmarinic acid (RA; Sigma) and a range of deodorised rosemary extracts. These had been prepared by selected extraction with either organic solvents or CO₂ to obtain extracts containing 35% phenolic diterpenes (35RE; Danisco) and a rosemary extract containing 6% rosmarinic acid (6RA; Danisco). Enhanced nisin activity was evident with a combination of nisin combined with pure rosmarinic acid (RA; this may have partly been due to low pH levels), a combination of nisin with a rosemary extract containing 6% rosmarinic acid (6RA) and a combination of nisin with a deodorised rosemary extract containing 35% phenolic diterpenes and < 1% essential oils (35RE). The known nisin synergy with Tween 80 was also observed. The other carrier propylene glycol did not enhance nisin activity. The synergies can be observed, as before, by comparing the MIC levels for 10 nisin alone, the other test compound, and the two together (see Table 5).

15

20

Table 5. MIC after growth at 30 °C in laboratory medium

Test organism	MIC in Bioscreen after 24 h at 30 °C	
	Individual components	Combination with nisin
<i>L. monocytogenes</i> strain S23	Nisin at 1000 IU/ml	-
	0.1% GRE09	0.05% GRE09 + 50 IU/ml nisin
	1% RA	0.25% RA + 250 IU/ml nisin 0.5% RA + 100 IU/ml nisin 0.75% RA + 50 IU/ml nisin

Test organism	MIC in Bioscreen after 24 h at 30 °C	
	Individual components	Combination with nisin
	1% 6RA	< 0.1% 6RA + 250 IU/ml nisin 0.5% 6RA + 50 IU/ml nisin
<i>L. monocytogenes</i> strain 272	500 IU/ml nisin	-
	0.25% GRE09	< 0.05% GRE09 + 50 IU/ml nisin
	1% of RE35	< 0.05% RE35 + 50 IU/ml nisin
	> 2% Tween 80	0.5% Tween 80 + 250 IU/ml nisin
<i>L. monocytogenes</i> strain NCTC12426	250 IU/ml nisin	-
	0.25% GRE09	< 0.05% GR 09 + 50 IU/ml nisin
	1% of RE35	< 0.05% RE35 + 50 IU/ml nisin
	> 2% Tween 80	0.5% Tween 80 + 100 IU/ml nisin
<i>B. cereus</i> Campden spores	500 IU/ml nisin	-
	0.1% GRE09	0.05% GRE09 + 50 IU/ml
	1% RA	0.5% RA + 250 IU/ml nisin 0.75% RA + 100 IU/ml nisin 0.75% RA + 50 IU/ml nisin
	1% 6RA	0.25% 6RA + 100 IU/ml nisin 0.5% 6RA + 50 IU/ml nisin

IV) Demonstration of synergy for nisin activity with different deodorised rosemary extract components in food

5 Test strains: *Listeria monocytogenes* strains 272, CRA3930 and NCTC12426

The chicken soup model was used as before. The following samples were tested: GRE09, deodorised rosemary extracts containing 35% or 70% phenolic diterpenes (RE35 and RE70; Danisco), a water soluble rosemary extract containing 6% rosmarinic acid (6RA; Danisco) and pure rosmarinic acid (RA; Sigma). Additions to the soup were made as appropriate. The soup was pasteurised (70 °C/ 2 minutes), the pH recorded and the soup was then inoculated with a cocktail of *Listeria* cells prepared as described before. The tests were incubated at 20 °C and viable count enumeration performed after 0, 2, 4 and 24 h at 20 °C. Initial *Listeria* levels were 1.3×10^5 CFU/ml. The test was repeated at two nisin levels and over different time periods. The pH of the soup without

addition was pH 6.06 - 6.20. Addition of rosmarinic acid at 0.1% resulted in a slight pH drop to pH 5.75. Addition of 6% RA resulted in a soup pH of pH 5.75-5.78. Addition of 0.5% RE35 resulted in a soup pH of pH 5.98. Addition of 0.5% RE70 resulted in a soup pH of pH 6.10. Addition of 0.5% GRE09 resulted in a soup pH of pH 6.02-6.09.

5

Results, shown in Figures 4 and 5, indicate that all the deodorised extracts tested and rosmarinic acid contributed to synergy with nisin in achieving kill of *Listeria* cells. This could not be attributed to the drop in pH caused by some of the additions. The additional synergy with Tween 80 was observed in GRE09. The results indicate that the 10 antioxidant compounds carnosol and carnosic acid, present at 35 and 70% in two of the extracts tested, synergistically enhanced the cidal and growth inhibitory activity of nisin against *Listeria monocytogenes*. A nisin synergy with rosmarinic acid was evident but not as strong.

REFERENCES**Bacteriocin + rosemary combination**

5 JP 07-03955 & JP 3042573 (Asam Kasei KK, Lion Corp)
 JP 3040282 (Asam Kasei KK)

Nisin + Tween 80 synergy

10 Jung, D. -S, Bodyfelt, F. W. and Daeschel, M. 1992. Influence of fat and emulsifiers on the efficacy of nisin in inhibiting *Listeria monocytogenes* in fluid milk. *Journal of Dairy Science* 75: 387-393

Synergy between essential oils and nisin

15 Pol, I. E., Krommer, J., and Smid, E. 2002. Bioenergetic consequences of nisin combined with carvacrol towards *Bacillus cereus*. *Innovative Food Science and Emerging Technologies* 3: 55-61.

20 Pol, I. E. and Smid, E. J. 1999. Combined action of nisin and carvacrol on *Bacillus cereus* and *Listeria monocytogenes*. *Letters in Applied Microbiology* 29: 166- 170.

25 Pol, I. E. 2001. Improved applicability of nisin in novel combinations with other food preservation factors. Ph.D thesis Wageningen University, The Netherlands ISBN 90-5808-382-9

Periago, P. M., Palop, A., Fernandez, P. S. 2001. Combined effect of nisin, carvacrol and thymol on the viability of *Bacillus cereus* treated vegetative cells. *Food Science and Technology International* 7: 487-492.

30 **Antimicrobial activity of rosemary**

Aureli, P., Constantini, A., and Zolea, S. 1992. Antimicrobial activity of some plant essential oils against *Listeria monocytogenes*. *Journal of Food Protection* 55:344-348.

Azzouz, M. A. and Bullerman, L. B. 1982. Comparative antimycotic effects of selected herbs, spices, plant components and commercial antifungal agents. *Journal of Food Protection* 45: 1298-1301

5 Collins, M. A., and Charles, H. P. 1987. Antimicrobial activity of Carnosol and Ursolic acid: two anti-oxidant constituents of *Rosmarinus officinalis* L. *Food Microbiology* 4: 311-315

Deans, S. G. and Ritchie, G. 1987. Antibacterial activity of plant essential oils.

10 International Journal of Food Microbiology 5: 165-180.

Del Campo, J., Amiot, M. -J., and Nguyen-The, C. 2000. Antimicrobial effect of Rosemary extracts. *Journal of Food Protection*. 63:1359-1368.

15 Del Campo, J., Amiot, M. -J., Lapierre, C., and Nguyen-The, C. 1998. Antimicrobial activity of phenolic extracts from rosemary. 2nd International Electronic Conference on Synthetic Organic Chemistry (ECS)C-2), <http://www.mdpi.org/ecsoc/>, September 1-30, 1998

20 Eiserle, R. J. 1971. Gemini rising – a natural flavouring and stabilisation system for food. *Food Prod. Dev.* 10: 70 – 71

Farag, R. S., Daw, Z. Y., Hewedi, F. M. and El-Baroty, G. S. A. 1989. Antimicrobial activity of some Egyptian spice essential oils. *Journal of Food Protection* 52: 665-667

25 Farbood, M. I., MacNeil, J. H. and Ostovar, K. 1976. Effect of Rosemary spice extractive on growth of micro-organisms in meat. *Journal of Milk Food Technology*. 39:675-679

30 MacNeil, J. H., Dimick, P. S., and Mast, M. G. 1973. Use of chemical compounds and a rosemary spice extractive in quality maintenance of deboned poultry meat. *Journal of Food Science* 38: 1080-1081

35 MacNeil, J. H., and Mast, M. G. 1973. Frankfurters without nitrates and nitrites. *Food Prod. Dev.* 7: 36- 40

Pandit, V. A. and Shelef, L. A. 1994. Sensitivity of *Listeria monocytogenes* to rosemary. *Food Microbiology* 11: 57-63

5 Shelef, L. A. 1983. Antimicrobial effects of spices. *Journal of Food Safety* 6:29-44

Shelef, L. A., Naglik, O. A., and Bogen, D. W. 1980. Sensitivity of some common food-borne bacteria to the spices sage, rosemary and allspice. *Journal of Food Science* 45:1042-1044

10 Valero, M. and Salmeron, M. C. 2003. Antibacterial activity of 11 essential oils against *Bacillus cereus* in tyndallized carrot broth. *International Journal of Food Microbiology* 85: 73-81

15 Zaika, L. L. 1988. Spices and herbs: their antimicrobial activity and its determination. *Journal of Food Safety* 9:97-118

Antimicrobial activity of sage

20 Akgul, A. and Kivanc, M. 1989. Sensitivity of four foodborne moulds to essential oils from Turkish spices, herbs and citrus peel. *J. Sci. Food Agric.* 47: 129 – 132

Aureli, P., Constantini, A., and Zolea, S. 1992. Antimicrobial activity of some plant essential oils against *Listeria monocytogenes*. *Journal of Food Protection* 55:344-348

25 Azzouz, M. A.. and Bullerman, L. B. 1982. Comparative antimycotic effects of selected herbs, spices, plant components and commercial antifungal agents. *Journal of Food Protection* 45: 1298-1301

30 Deans, S. G. and Ritchie, G. 1987. Antibacterial activity of plant essential oils. *International Journal of Food Microbiology* 5: 165-180

Farag, R. S., Daw, Z. Y., Hewedi, F. M. and El-Baroty, G. S. A. 1989. Antimicrobial activity of some Egyptian spice essential oils. *Journal of Food Protection* 52: 665-667

Haq, I. 1982. Bull. Islamic Med. 2: 496

Ikram, M. and Haq, I. 1980. Screening of medicinal plants for antimicrobial activity.
Part I. Fitoterapia 51: 231- 235.

5

Leslie, G. B. 1978. Medita B 10: 3

Moujir, L., Gutierrez-Navarro, A. M., Andres, L. S. Luis, J. G. 1993. Structure-
antimicrobial activity relationships of abietane diterpenes from *Salvia* species.

10 Phytochemistry 34: 1493-1495

Ross, S. A., El-Ketawi, N. E. and Megalla, S. E. 1980. Antimicrobial activity of some
Eqyptian aromatic plants. Fitoterapia 51: 201-205.

15 Shelef, L. A.; Naglik, O. A., and Bogen, D. W. 1980. Sensitivity of some common
food-borne bacteria to the spices sage, rosemary and allspice. Journal of Food Science
45:1042-1044

Phenolic diterpenes in sage and rosemary

20

Brieskorn, C., and H. J. Domling. 1969. Carnosolsaure, der Wichtige Antioxidative
Wirksame Inhaltsstoff des Rosmarin- und Salbeiblattes. Z. Leibensmittel Unters.
Forsch. 41: 10 – 16

25 Cuvelier, M. O.E., Richard, H., and Berset, C. 1996. Antioxidative activity and phenolic
composition of pilot-plant and commercial extracts of sage and rosemary. JAOCS 73:
645-652

30 Ford, B. A. and Hill, V. A. 2001. Chewing gum base stabilized with carnosic acid. &
US 6231896 B1

Lamaison, J. –L., C. Petitjean-Freytet, and A. Carnat. 1991. Lamiacées Médicinales à
Propriétés Antioxydantes, source Potentielles d'acide Rosmarinique. Pharm. Acta Helv.
66: 185-188

10 Loliger, J. 1989. Natural Antioxidants. In: Rancidity in Food, edited by J. Allen and R. Hamilton. Elsevier Applied Science, New York, pp 105-124

15 Schuler, P. 1990. Natural Antioxidants Exploited Commercially. In Food Antioxidants, edited by B. Hudson. Elsevier Applied Science, New York. Pp. 99-170

Enhancement of nisin by emulsifiers or chelators

US5217950

10

US5691301

Antimicrobial activity of plant extracts: general reviews

15 Nychas, G.-J. E., Skandamis, P. N. 2003. Antimicrobials from herbs and spices. In: Natural Antimicrobials for the Minimal Processing of Foods. Ed: S. Roller. CRC Press. Washington, USA.

20 Smid, E. J. and Gorris, L. G. M. 1999. Natural antimicrobials for food preservation. In: Handbook of Food Preservation. Ed: M. S. Rahman. Marcel Dekker Inc. New York.

Enhancement of nisin with lytic enzyme (lysozyme)

US 5458876

25

EP 0427912

EP 0374823

30 **Nisin use in food**

Thomas, L. V., Clarkson, M. R., Delves-Broughton, J. 2000. Nisin. In: Natural food antimicrobials systems. pp. 463-524. CRC Press, Boca Raton, USA

35 Delves-Broughton, J. 1990. Nisin and its use as a food preservative. Food Technology.

44: 100, 102, 104, 106, 108, 111-112, 117.

De Vuyst, De Vuyst, L., and Vandamme, E. J. 1994. Nisin, a lantibiotic produced by *Lactococcus lactis* subsp. *lactis*: properties, biosynthesis, fermentation and applications.

5 In: Bacteriocins of lactic acid bacteria. Microbiology, Genetics and Applications. Eds: De Vuyst and Vandamme. Blackie Academic and Professional. London.

Thomas, L. V. and Delves-Broughton, J. 2001. New advances in the application of the food preservative nisin. Research Advances in Food Science 2: 11-22.

10

Nisin regulations

Turtell, A. and Delves-Broughton, J. 1998. International acceptance of nisin as a food preservative. Bull. Int. Dairy Fed. 329: 20-23

15

Bacteriocins

Naidu, A. S. (Ed.) 2000. Natural Food Antimicrobial Systems. USA: CRC Press.

20 Ray, B., and Miller, K. W. 2003. Bacteriocins other than nisin: the pediocin-like cystibiotics of lactic acid bacteria. In: Natural Antimicrobials for the Minimal Processing of Foods. Ed: Sibel Roller. CRC Press, USA.

25 Ray, B. and Daeschel, M. A. 1994. Bacteriocins of starter culture bacteria. In: Natural Antimicrobial Ssytems and Food Preservation. 1994. Ed: Dillon, V. M. and Board, R. G. CAB International, UK, pp 133 – 166.

Axelsen, L. 1998. Lactic acid bacteria: classification and physiology'. In: Salminen, S. and von Wright, A. In: Lactic Acid Bacteria. 2nd Ed. New York, Marcel Dekker, pp 1-72.

30

Ray, B., Miller, K. W. and Jain, M. K. 2001. Bacteriocins of lactic acid bacteria. Indian Journal of Microbiology 41: 1-21.

35 Hoover, D. G. 1993. Bacteriocins with potential for use in foods. In: Antimicrobials in Foods. Ed: P. M. Davidson and A. L. Branen. Marcel Dekker, USA.

Wessels, S., Jelle, B., and Nes, I. F. 1998. Bacteriocins of the Lactic Acid Bacteria. Danish Toxicology Centre, Denmark.

5 **Pediocin**

Ray, B., and Miller, K. W. 2000. Pediocin. In: Natural Food Antimicrobial Systems, ed. A. S. Naidu. Pp. 525-566. USA: CRC Press

10 All publications mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described methods and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed
15 should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in chemistry, biology, food science or related fields are intended to be within the scope of the following claims

CLAIMS

1. A composition comprising
 - (a) an antimicrobial material; and
 - 5 (b) an extract obtained from or obtainable from a plant of the Labiatae family, wherein (a) and (b) are different wherein when the antimicrobial material consists of nisin, the composition comprises carvacrol in an amount of less than 0.075wt.% based on the composition and carvone in an amount of less than 15wt.% based on the composition.
- 10 2. A composition according to claim 1 wherein the composition comprises carvacrol in an amount of less than 0.075wt.% based on the composition.
3. A composition according to claim 1 or 2 wherein the composition comprises each 15 of thymol and eugenol in amounts of less than 15wt.% based on the composition.
4. A composition according to claim 1, 2 or 3 wherein the composition comprises carvacrol in an amount of less than 0.075wt.% based on the composition.
- 20 5. A composition according to any one of claims 1 to 4 wherein the antimicrobial material is a bacteriocin.
6. A composition according to any one of claims 1 to 5 wherein the bacteriocin is selected from lanthionine containing bacteriocins, *Lactococcus*-derived bacteriocins, 25 *Streptococcus*-derived bacteriocins, *Pediococcus*-derived bacteriocins, *Lactobacillus*-derived bacteriocins, *Carnobacterium*-derived bacteriocins, *Leuconostoc*-derived bacteriocins, *Enterococcus*-derived bacteriocins and mixtures thereof
- 30 7. A composition according to any one of claims 1 to 6 wherein the bacteriocin is at least nisin.
8. A composition according to any one of claims 1 to 7 wherein the extract is obtained from a plant of the Labiatae family.
- 35 9. A composition according to any one of claims 1 to 8 wherein the plant of the

Labiatae family is selected from rosemary, sage, oregano, marjoram, mint, balm, savoury, and thyme.

10. A composition according to any one of claims 1 to 9 wherein the plant of the
5 Labiatae family is selected from rosemary, sage, oregano, marjoram, mint, balm, and
savoury.

11. A composition according to any one of claims 1 to 10 wherein the plant of the
Labiatae family is rosemary.

10 12. A composition according to any one of claims 1 to 11 wherein the extract is
selected from phenolic diterpenes, phenolic triterpenes and rosmarinic acid.

13. A composition according to claim 12 wherein the phenolic diterpene is selected
15 from carnosic acid, carnosol and methylcarnosic acid.

14. A composition according to claim 13 wherein the phenolic triterpene is selected
from betulinic acid, oleanolic acid, and ursolic acid.

20 15. A composition according to any one of claims 1 to 14 wherein the combined
amount of phenolic diterpenes, and phenolic triterpenes and rosmarinic acid, based on
the composition, is greater than 3.5 wt.%.

25 16. A composition according to any one of claims 1 to 15 wherein the amount of
phenolic diterpenes, based on the composition, is greater than 1.0 wt.%, preferably
greater than 3.5 wt.%.

17. A composition according to any one of claims 1 to 16 wherein the amount of
phenolic triterpenes, based on the composition, is greater than 3.5 wt.%.

30 18. A composition according to any one of claims 1 to 17 wherein the amount of
rosmarinic acid, based on the composition, is greater than 3.5 wt.%.

35 19. A composition according to any one of claims 1 to 18 wherein the extract contains
flavour-inducing compounds and/or essential oils in an amount of less than 1 wt.% based

on the composition.

20. A composition according to any one of claims 1 to 19 wherein the extract contains essential oils in an amount of less than 1 wt.% based on the composition.

5

21. A composition according to any one of claims 1 to 20 wherein the antimicrobial material and/or the extract are present in an amount to provide a microbicidal or microbiostatic effect.

10 22. A composition according to any one of claims 1 to 21 wherein the antimicrobial material and the extract are present in an amount to provide a microbicidal or microbiostatic effect.

15 23. A composition according to any one of claims 1 to 22 wherein the antimicrobial material and the extract are present in an amount to provide a microbicidal or microbiostatic synergistic effect.

20 24. A composition according to any one of claims 1 to 23 wherein the antimicrobial material and the extract are present in an amount to provide a microbicidal synergistic effect.

25 25. A composition according to any one of claims 21 to 24 wherein the microbicidal or microbiostatic effect is a bactericidal or bacteriostatic effect.

25 26. A composition according to claim 25 wherein the bactericidal or bacteriostatic effect is in respect of Gram-positive bacteria.

30 27. A composition according to claim 26 wherein the bactericidal or bacteriostatic effect is in respect of an organism selected from species of *Bacillus*, species of *Clostridium*, *Listeria monocytogenes*, lactic acid bacteria, and *Lactobacillus* species.

28. A composition according to any one of claims 25 to 27 wherein the bactericidal or bacteriostatic effect is in respect of *Listeria monocytogenes*.

35 29. A composition according to any one of claims 1 to 28 wherein the composition is

a foodstuff.

30. A composition according to any one of claims 1 to 28 wherein the composition is a protectant composition suitable for addition to a foodstuff.

5

31. A composition according to claim 29 or 30 the foodstuff is selected from raw meat, cooked meat, raw poultry products, cooked poultry products, raw seafood products, cooked seafood products, ready to eat meals, pasta sauces, pasteurised soups, mayonnaise, salad dressings, oil-in-water emulsions, margarines, low fat spreads, water-in-oil emulsions, dairy products, cheese spreads, processed cheese, dairy desserts, flavoured milks, cream, fermented milk products, cheese, butter, condensed milk products, ice cream mixes, soya products, pasteurised liquid egg, bakery products, confectionery products, fruit products, and foods with fat-based or water-containing fillings.

15

32. A composition according to any one of claims 1 to 33 wherein the composition further comprises an emulsifier.

20

33. A composition according to claim 32 wherein the emulsifier is selected from polysorbates, monoglycerides, diglycerides, acetic acid esters of mono-diglycerides, tartaric acid esters of mono-diglycerides and citric acid esters of mono-diglycerides.

34. A composition according to any one of claims 1 to 33 wherein the composition further comprises a chelator.

25

35. A composition according to claim 34 wherein the chelator is selected from EDTA, citric acid, monophosphates, diphosphates, triphosphates and polyphosphates.

30

36. A composition according to claim 34 or 35 wherein the chelator enhances the antimicrobial activity and/or antimicrobial spectrum of the antimicrobial material.

37. A composition according to claim 34, 35 or 36 wherein the chelator enhances the antimicrobial activity and/or antimicrobial spectrum of the antimicrobial material in respect of Gram-negative bacteria.

35

38. A composition according to any one of claims 1 to 29 wherein the composition further comprises a lytic enzyme.

39. A composition according to claim 38 wherein the lytic enzyme is a lysozyme.

5

40. A composition according to claim 1 comprising

(a) an antimicrobial material, wherein the antimicrobial material is nisin; and

(b) an extract obtained from a plant of the Labiatae family, wherein the extract is a phenolic triterpene selected from betulinic acid, oleanolic acid or ursolic acid wherein the

10 antimicrobial material and the extract are present in an amount to provide a bactericidal or bacteriostatic synergistic effect.

41. A composition according to claim 1 comprising

(a) an antimicrobial material, wherein the antimicrobial material is nisin; and

15 (b) an extract obtained from a plant of the Labiatae family, wherein the extract is rosmarinic acid,

wherein the antimicrobial material and the extract are present in an amount to provide a bactericidal or bacteriostatic synergistic effect.

20 42. A process for preventing and/or inhibiting the growth of, and/or killing a micro-organism in a material, the process comprising the step of contacting the material with

(a) an antimicrobial material; and

(b) an extract obtained from or obtainable from a plant of the Labiatae family,

wherein (a) and (b) are different

25 wherein when the antimicrobial material consists of nisin, the composition comprises carvacrol in an amount of less than 0.075wt.% based on the composition and carvone in an amount of less than 15wt.% based on the composition.

30 43. A process according to claim 42 wherein the antimicrobial material and the extract are added to the material together.

44. A process according to claim 42 wherein the antimicrobial material and the extract are added to the material sequentially.

35 45. A process according to any one of claims 42 to 44 wherein the bacteriocin is

added to the material.

46. A process according to claim 42 wherein the bacteriocin is formed *in situ* in the material.

5

47. A process according to any one of claims 42 to 46 wherein the material is a foodstuff.

48. A process according to any one of claims 42 to 47 characterised by the features
10 of any one of claim 2 to 41.

49. Use of (a) an antimicrobial material; and b) an extract obtained from or obtainable
from a plant of the Labiatae family, for preventing and/or inhibiting the growth of, and/or
killing a micro-organism in a material; wherein (a) and (b) are different; and wherein when
15 the antimicrobial material consists of nisin, the composition comprises carvacrol in an
amount of less than 0.075wt.% based on the composition and carvone in an amount of
less than 15wt.% based on the composition.

50. Use according to claim 49 wherein the material is a foodstuff.

20

51. Use according to claim 49 or 50 for synergistically preventing and/or inhibiting the
growth of, and/or killing a micro-organism in a material.

52. Use according to any one of claims 49 to 51 characterised by the features of any
25 one of claim 2 to 41.

53. A kit for preparing a composition as defined in any one of claims 1 to 41, the kit
comprising

(a) an antimicrobial material; and

30 (b) an extract obtained from or obtainable from a plant of the Labiatae family,
wherein (a) and (b) are different
in separate packages or containers; optionally with instructions for admixture and/or
contacting and/or use.

35 54. A composition as substantially hereinbefore described with reference to any one

of the Examples.

55. A process as substantially hereinbefore described with reference to any one of the Examples.

5

56. A use as substantially hereinbefore described with reference to any one of the Examples.

57. A kit as substantially hereinbefore described with reference to any one of the

10 Examples.

ABSTRACT**COMPOSITION**

5

The present invention provides a composition comprising (a) an antimicrobial material; and (b) an extract obtained from or obtainable from a plant of the Labiatae family, wherein (a) and (b) are different; wherein when the antimicrobial material consists of nisin, the composition comprises carvacrol in an amount of less than 0.075wt.% based 10 on the composition and carvone in an amount of less than 15wt.% based on the composition.

Figure 1




Figure 1. Synergistic enhancement of nisin cidal activity against *Listeria monocytogenes* in chicken soup at 25 °C by a rosemary extract




Figure 2. Synergistic enhancement of nisin control of *Listeria monocytogenes* growth in chilled chicken soup by a rosemary extract (GRE09)




Figure 3. Synergistic enhancement by a rosemary extract of nisin control of *B. cereus* spore outgrowth in chilled chicken soup. Minimal detection limit was 100 CFU/g. For the length of the testing period, the samples containing the combination of nisin and rosemary had *Bacillus* counts at or below 100 CFU/g.




Figure 4. Combined effect of nisin, selectively extracted rosemary extracts and rosemary extract components against *L. monocytogenes* in chicken soup at 20 °C (Minimum detection limit 100 CFU/g)




Figure 5. Synergistic enhancement of nisin activity by extracts of rosemary or rosmarinic acid against *Listeria monocytogenes* in a chicken soup at ambient temperature.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.